<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>Chimeric antigen receptor T (CAR-T) cell therapy has been proven to be successful against different leukaemias and lymphomas. Its success has led, in recent years, to its use being tested for different solid tumours, including glioblastoma, a type of primary brain tumour, characterised by aggressiveness and recurrence. This paper presents an analytical study of a mathematical model describing the competition of CAR-T and glioblastoma tumour cells, taking into account their immunosuppressive capacity. The model is formulated in a general way, and its basic properties are investigated. However, most of the analysis considers the model with exponential tumour growth, assuming this growth type for simplicity. The existence and stability of steady states are studied, and the subsequent focus is on two different types of treatment: constant and periodic. Finally, protocols for CAR-T cell therapy of glioblastoma are numerically derived; these are aimed at preventing the tumour from reaching a critical size and at prolonging the patients’ survival time as much as possible. The analytical and numerical results provide theoretical support for the treatment of glioblastoma using CAR-T cells.</p>
</abstract>

Chimeric antigen receptor T (CAR-T) cell therapy has been proven to be successful against different leukaemias and lymphomas. Its success has led, in recent years, to its use being tested for different solid tumours, including glioblastoma, a type of primary brain tumour, characterised by aggressiveness and recurrence. This paper presents an analytical study of a mathematical model describing the competition of CAR-T and glioblastoma tumour cells, taking into account their immunosuppressive capacity. The model is formulated in a general way, and its basic properties are investigated. However, most of the analysis considers the model with exponential tumour growth, assuming this growth type for simplicity. The existence and stability of steady states are studied, and the subsequent focus is on two different types of treatment: constant and periodic. Finally, protocols for CAR-T cell therapy of glioblastoma are numerically derived; these are aimed at preventing the tumour from reaching a critical size and at prolonging the patients’ survival time as much as possible. The analytical and numerical results provide theoretical support for the treatment of glioblastoma using CAR-T cells.

On the Analysis of a Mathematical Model of CAR–T Cell Therapy for Glioblastoma: Insights from a Mathematical Model

University of Warmia and Mazury in Olsztyn

International Journal of Applied Mathematics and Computer Science

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Chimeric antigen receptor T (CAR-T) cell therapy has been proven to be successful against different leukaemias and lymphomas. Its success has led, in recent...

On the Analysis of a Mathematical Model of CAR–T Cell Therapy for Glioblastoma: Insights from a Mathematical Model

Online veröffentlicht: 21. Sept. 2023

Seitenbereich: 379 - 394

Eingereicht: 12. Okt. 2022

Akzeptiert: 15. Mai 2023

DOI: https://doi.org/10.34768/amcs-2023-0027

Schlüsselwörter
glioblastoma, CAR-T cell therapy, mathematical modelling, periodic treatment

© 2023 Marek Bodnar et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

On the Analysis of a Mathematical Model of CAR–T Cell Therapy for Glioblastoma: Insights from a Mathematical Model

Online veröffentlicht: 21. Sept. 2023

Seitenbereich: 379 - 394

Eingereicht: 12. Okt. 2022

Akzeptiert: 15. Mai 2023

DOI: https://doi.org/10.34768/amcs-2023-0027

Schlüsselwörterglioblastoma, CAR-T cell therapy, mathematical modelling, periodic treatment

© 2023 Marek Bodnar et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Schlüsselwörter
glioblastoma, CAR-T cell therapy, mathematical modelling, periodic treatment